Keyphrases
Pembrolizumab
100%
Dabrafenib
100%
Bilateral Uveitis
100%
Acute Uveitis
25%
Young Female
12%
Uveitis
12%
Metastatic Melanoma
12%
Targeted Agents
12%
Ophthalmological
12%
Adult Female
12%
Same Patient
12%
Melanoma
12%
Oral Corticosteroids
12%
Corticosteroid Therapy
12%
Anterior Uveitis
12%
Checkpoint Inhibitors
12%
Escalating Dose
12%
Photophobia
12%
Oral Steroids
12%
Topical Steroid Therapy
12%
Topical Corticosteroids
12%
Blurry Vision
12%
Third Dose
12%
Recurrent Uveitis
12%
Advanced Metastatic Melanoma
12%
Bilateral Panuveitis
12%
Medicine and Dentistry
Uveitis
100%
Pembrolizumab
100%
Dabrafenib
100%
Metastatic Melanoma
25%
Side Effect
12%
Corticosteroid Therapy
12%
Steroid Therapy
12%
Topical Corticosteroid
12%
Photophobia
12%
Iridocyclitis
12%
Melanoma
12%
Pharmacology, Toxicology and Pharmaceutical Science
Uveitis
100%
Pembrolizumab
100%
Dabrafenib
100%
Metastatic Melanoma
25%
Side Effect
12%
Melanoma
12%
Iridocyclitis
12%
Topical Corticosteroid
12%
Photophobia
12%
Neuroscience
Uveitis
100%
Lambrolizumab
100%
Dabrafenib
100%
Anterior Uveitis
12%
Panuveitis
12%
Topical Steroid
12%